Market Research Life Sciences Market Research Pharmaceuticals Market Research Manufacturing, Packaging & Detailing Market Research

Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

Price Length Publisher Published Date SKU
from $4,977 370 Pages Visiongain November, 2022 VSG17530884
Price from $4,977
Length 370 Pages
Publisher Visiongain
Published Date November, 2022
SKU VSG17530884

Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

The Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

The pharmaceutical industry is going through significant changes that are altering its business models, according to our analyst. This represents one of the new opportunities for market participants in the global pharmaceutical contract manufacturing organisations. According to our analysis, the pharmaceutical contract manufacturing organisations (CMOs) market is estimated to be valued at US$1,04,396 million in 2022 and is projected to reach a market value of US$2,03,240 million by 2032.

Growing Demand and Acceptability of Biosimilars Can Be Seen as a Big Opportunity for Pharma CMOs

Growing demand and acceptability of biosimilars can be seen as a big opportunity for contract manufacturing and research organisations. The requirement of affordable healthcare and upcoming patent expiries of innovative biologic drugs offers significant opportunities for biosimilars. Large pharma and biopharma companies see a huge opportunity in biosimilars. Rather than jump into the market on their own, most are interested in sharing their risks and working with collaborators. They are forming joint ventures or partnerships with the outsourcing providers. For Instance, in March 2022, Johnson & Johnson completed a historic agreement between Janssen Pharmaceuticals, Inc. and South African manufacturer Aspen SA Operations (Pty) Ltd to enable the first COVID-19 vaccine to be manufactured and made available by an African company for people living in Africa, with the goal of increasing COVID-19 vaccination rates across the continent.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the pharmaceutical contract manufacturing organisations (CMOs) market evolving?
  • What is driving and restraining the pharmaceutical contract manufacturing organisations (CMOs) market?
  • How will each pharmaceutical contract manufacturing organisations (CMOs) submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
  • What will be the main driver for the overall market from 2022 to 2032?
  • Will leading pharmaceutical contract manufacturing organisations (CMOs) markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the pharmaceutical contract manufacturing organisations (CMOs) projects for these leading companies?
  • How will the industry evolve during the period between 2022 and 2032? What are the implications of pharmaceutical contract manufacturing organisations (CMOs) projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the pharmaceutical contract manufacturing organisations (CMOs) market?
  • Where is the pharmaceutical contract manufacturing organisations (CMOs) market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the pharmaceutical contract manufacturing organisations (CMOs) market today, and over the next 10 years:
  • Our 370-page report provides 159 tables, 212 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them – NOW.
  • It contains in-depth analysis of global, regional growth analysis.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the top 50 pharmaceutical contract manufacturing organisations (CMOs) market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects
  • In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), PEST Analysis, Porter’s Five Forces Analysis
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regions
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East and Africa
The report also includes profiles and for some of the leading companies in the Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
  • Abbott Laboratories
  • AbbVie Inc.
  • Alkermes
  • AstraZeneca
  • Aurobindo Pharma
  • Avid Bioservices, Inc.
  • Bavarian Nordic
  • Baxter Biopharma Solutions
  • Bayer AG
  • BD
  • bioMérieux
  • Boston Scientific Corporation
  • CordenPharma International
  • Catalent Inc.
  • Consort Medical plc
  • CSL Limited
  • Divi's Laboratories Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Dupont
  • Edwards Lifesciences Corporation
  • Eli Lilly and Company
  • Emergent BioSolutions
  • Evonik Industries
  • F. Hoffmann-La Roche Ltd.
  • Fresenius SE&Co. KGaA
  • Gilead Sciences, Inc.
  • GSK plc
  • Grifols
  • Huapont Life Sciences Co Ltd.
  • INOVIO Pharmaceuticals
  • Johnson & Johnson Services Inc.
  • Koninklijke DSM N.V. (Royal DSM)
  • Lonza
  • McKesson Corporation
  • Merck KGaA
  • Moderna Inc.
  • Nipro Corporation
  • Novartis AG
  • Novavax
  • Novo Nordisk A/S
  • Pfizer Inc.
  • PPD Inc.
  • Sanofi
  • Strides Pharma Science Limited
  • Teva Pharmaceuticals Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • UPM Pharmaceuticals
  • VBI Vaccines Inc.
  • WuXi AppTec
  • ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.
Overall world revenue for Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032 in terms of value the market will surpass US$1,04,396 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022 report help you?

In summary, our 370-page report provides you with the following knowledge:
  • Revenue forecasts to 2032 for Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032 Market, with forecasts and company size, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2032 for five regional markets – See forecasts for the Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, South America, Middle East & Africa.
  • Prospects for established firms and those seeking to enter the market – including company profiles for 50 of the major companies involved in the Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher..

The publisher is using a password system to access single user and team licenses. Single user (non-printable) and team licenses expire after 12 month period. In the case of team license purchases, the publisher requires all email addresses for the licensed users prior to fulfilment.


1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Biosimilars Are Becoming Increasingly Popular
3.2.1.2 Increased Concentration on Orphan and Specialty Drugs
3.2.1.3 Demand for Formulation Development Services is Growing
3.2.1.4 Biopharmaceutical Companies Strive for Strategic Collaboration with Drug Delivery Technology Firms
3.2.1.5 Continued Concentration on Productivity
3.2.1.6 Advantage of Cost Savings is Driving the Market Growth
3.2.1.7 To Mitigate Risk Associated to New Drug Development
3.2.2 Market Restraining Factors
3.2.2.1 Product and Process Development is a Challenge
3.2.2.2 The Main Challenge for the CMOs is to Attract Companies Ready to Invest
3.2.2.3 Stringent Regulations Are Hindering the Market Growth
3.2.2.4 Pharmaceutical Manufacturers Are Facing Big Revenue Challenges with the Patent Expirations
3.2.2.5 Challenge Related to the High R&D Expenditures
3.2.2.6 Backwards Compatibility for Generics Manufacturers
3.2.3 Market Opportunities
3.2.3.1 Manufacturing and Packaging Capabilities Are Lacking
3.2.3.2 Pharma Firms will Continue to Look for Ways to Reduce Drug Costs
3.2.3.3 New Drug Delivery Technologies Are Required
3.2.3.4 Chemical APIs Will See a Resurgence Following the Shift in Focus to Biological APIs
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PESTLE Analysis
3.5.1 Political
3.5.2 Economic
3.5.3 Social
3.5.4 Technological
3.5.5 Environmental
3.5.6 Legal
4 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Analysis by Region
4.1 Key Findings
4.2 Regional Market Size Estimation and Forecast
5 Competitive Landscape
5.1 Company Share Analysis
5.2 Market Shares
5.2.1 Bulk Drugs and APIs
5.2.2 Solid Dosage Forms
5.2.3 Liquid Dosage Forms
5.2.3.1 Non-Sterile
5.2.3.2 Sterile
5.2.4 Semi-Solid Dosage Forms
6 Company Profiles
6.1 Johnson & Johnson Services Inc.
6.1.1 Company Snapshot
6.1.2 Company Overview
6.1.3 Financial Analysis
6.1.3.1 Net Revenue, 2017-2021
6.1.3.2 Operating Income, 2017-2021
6.1.3.3 Net Income, 2017-2021
6.1.3.4 EBITDA, 2017-2021
6.1.3.5 Company Regional Revenue Market Share
6.1.3.6 Company Business Segment Analysis
6.1.4 Service Benchmarking
6.1.5 Strategic Outlook
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Snapshot
6.2.2 Company Overview
6.2.3 Financial Analysis
6.2.3.1 Net Revenue, 2017-2021
6.2.3.2 Operating Income, 2017-2021
6.2.3.3 Net Income, 2017-2021
6.2.3.4 EBITDA, 2017-2021
6.2.3.5 Company Regional Revenue Market Share
6.2.3.6 Company Business Segment Analysis
6.2.4 Product Benchmarking
6.2.5 Strategic Outlook
6.3 Pfizer Inc.
6.3.1 Company Snapshot
6.3.2 Company Overview
6.3.3 Financial Analysis
6.3.3.1 Net Revenue, 2017-2021
6.3.3.2 Operating Income, 2017-2021
6.3.3.3 Net Income, 2017-2021
6.3.3.4 EBITDA, 2017-2021
6.3.3.5 Company Regional Revenue Market Share
6.3.4 Service Benchmarking
6.3.5 Strategic Outlook
6.4 Bayer AG
6.4.1 Company Snapshot
6.4.2 Company Overview
6.4.3 Financial Analysis
6.4.3.1 Net Revenue, 2017-2021
6.4.3.2 Operating Income, 2017-2021
6.4.3.3 Net Income, 2017-2021
6.4.3.4 EBITDA, 2017-2021
6.4.3.5 Company Regional Revenue Market Share
6.4.3.6 Company Business Segments Analysis
6.4.4 Product Benchmarking
6.4.5 Strategic Outlook
6.5 Novartis AG
6.5.1 Company Snapshot
6.5.2 Company Overview
6.5.3 Financial Analysis
6.5.3.1 Net Revenue, 2017-2021
6.5.3.2 Operating Income, 2017-2021
6.5.3.3 Net Income, 2017-2021
6.5.3.4 EBITDA, 2017-2021
6.5.3.5 Company Regional Revenue Market Share
6.5.3.6 Company Business Segments Analysis
6.5.4 Service Benchmarking
6.5.5 Strategic Outlook
6.6 CordenPharma International
6.6.1 Company Snapshot
6.6.2 Company Overview
6.6.3 Service Benchmarking
6.6.4 Strategic Outlook
6.7 GSK plc
6.7.1 Company Snapshot
6.7.2 Company Overview
6.7.3 Financial Analysis
6.7.3.1 Net Revenue, 2017-2021
6.7.3.2 Operating Income, 2017-2021
6.7.3.3 Net Income, 2017-2021
6.7.3.4 EBITDA, 2017-2021
6.7.3.5 Company Regional Revenue Market Share
6.7.3.6 Company Business Segments Analysis
6.7.4 Service Benchmarking
6.7.5 Strategic Outlook
6.8 Sanofi
6.8.1 Company Snapshot
6.8.2 Company Overview
6.8.3 Financial Analysis
6.8.3.1 Net Revenue, 2017-2021
6.8.3.2 Operating Income, 2017-2021
6.8.3.3 Net Income, 2017-2021
6.8.3.4 EBITDA, 2017-2021
6.8.3.5 Company Regional Revenue Market Share
6.8.3.6 Company Business Segments Analysis
6.8.4 Service Benchmarking
6.8.5 Strategic Outlook
6.9 AbbVie Inc.
6.9.1 Company Snapshot
6.9.2 Company Overview
6.9.3 Financial Analysis
6.9.3.1 Net Revenue, 2017-2021
6.9.3.2 Operating Income, 2017-2021
6.9.3.3 Net Income, 2017-2021
6.9.3.4 EBITDA, 2017-2021
6.9.3.5 Company Regional Revenue Market Share
6.9.3.6 Company Business Segments Analysis
6.9.4 Service Benchmarking
6.9.5 Strategic Outlook
6.10 Abbott Laboratories
6.10.1 Company Snapshot
6.10.2 Company Overview
6.10.3 Financial Analysis
6.10.3.1 Net Revenue, 2017-2021
6.10.3.2 Operating Income, 2017-2021
6.10.3.3 Net Income, 2017-2021
6.10.3.4 EBITDA, 2017-2021
6.10.3.5 Company Regional Revenue Market Share
6.10.3.6 Company Business Segments Analysis
6.10.4 Service Benchmarking
6.10.5 Strategic Outlook
6.11 Thermo Fisher Scientific Inc.
6.11.1 Company Snapshot
6.11.2 Company Overview
6.11.3 Financial Analysis
6.11.3.1 Net Revenue, 2017-2021
6.11.3.2 Operating Income, 2017-2021
6.11.3.3 Net Income, 2017-2021
6.11.3.4 EBITDA, 2017-2021
6.11.3.5 Company Regional Revenue Market Share
6.11.3.6 Company Business Segment Analysis
6.11.4 Service Benchmarking
6.11.5 Strategic Outlook
6.12 AstraZeneca
6.12.1 Company Snapshot
6.12.2 Company Overview
6.12.3 Financial Analysis
6.12.3.1 Net Revenue, 2017-2021
6.12.3.2 Operating Income, 2017-2021
6.12.3.3 Net Income, 2017-2021
6.12.3.4 EBITDA, 2017-2021
6.12.3.5 Company Regional Revenue Market Share
6.12.3.6 Company Business Segments Analysis
6.12.4 Service Benchmarking
6.12.5 Strategic Outlook
6.13 Eli Lilly and Company
6.13.1 Company Snapshot
6.13.2 Company Overview
6.13.3 Financial Analysis
6.13.3.1 Net Revenue, 2017-2021
6.13.3.2 Operating Income, 2017-2021
6.13.3.3 Net Income, 2017-2021
6.13.3.4 EBITDA, 2017-2021
6.13.3.5 Company Regional Revenue Market Share
6.13.3.6 Company Business Segments Analysis
6.13.4 Service Benchmarking
6.13.5 Strategic Outlook
6.14 Gilead Sciences, Inc.
6.14.1 Company Snapshot
6.14.2 Company Overview
6.14.3 Financial Analysis
6.14.3.1 Net Revenue, 2017-2021
6.14.3.2 Operating Income, 2017-2021
6.14.3.3 Net Income, 2017-2021
6.14.3.4 EBITDA, 2017-2021
6.14.4 Service Benchmarking
6.14.5 Strategic Outlook
6.15 DuPont
6.15.1 Company Snapshot
6.15.2 Company Overview
6.15.3 Financial Analysis
6.15.3.1 Net Revenue, 2017-2021
6.15.3.2 Operating Income, 2017-2021
6.15.3.3 Net Income, 2017-2021
6.15.3.4 EBITDA, 2017-2021
6.15.4 Service Benchmarking
6.15.5 Strategic Outlook
6.16 Novo Nordisk A/S
6.16.1 Company Snapshot
6.16.2 Company Overview
6.16.3 Financial Analysis
6.16.3.1 Net Revenue, 2017-2021
6.16.3.2 Operating Income, 2017-2021
6.16.3.3 Net Income, 2017-2021
6.16.3.4 EBITDA, 2017-2021
6.16.3.5 Company Regional Revenue Market Share
6.16.3.6 Company Business Segments Analysis
6.16.4 Service Benchmarking
6.16.5 Strategic Outlook
6.17 Merck KGaA
6.17.1 Company Snapshot
6.17.2 Company Overview
6.17.3 Financial Analysis
6.17.3.1 Net Revenue, 2017-2021
6.17.3.2 Operating Income, 2017-2021
6.17.3.3 Net Income, 2017-2021
6.17.3.4 EBITDA, 2017-2021
6.17.4 Service Benchmarking
6.17.5 Strategic Outlook
6.18 BD
6.18.1 Company Snapshot
6.18.2 Company Overview
6.18.3 Financial Analysis
6.18.3.1 Net Revenue, 2017-2021
6.18.3.2 Operating Income, 2017-2021
6.18.3.3 Net Income, 2017-2021
6.18.3.4 EBITDA, 2017-2021
6.18.3.5 Company Regional Revenue Market Share
6.18.3.6 Company Business Segments Analysis
6.18.4 Service Benchmarking
6.18.5 Strategic Outlook
6.19 Teva Pharmaceuticals Industries Ltd.
6.19.1 Company Snapshot
6.19.2 Company Overview
6.19.3 Financial Analysis
6.19.3.1 Net Revenue, 2017-2021
6.19.3.2 Operating Income, 2017-2021
6.19.3.3 Net Income, 2017-2021
6.19.3.4 EBITDA, 2017-2021
6.19.4 Service Benchmarking
6.19.5 Strategic Outlook
6.20 Evonik Industries
6.20.1 Company Snapshot
6.20.2 Company Overview
6.20.3 Service Benchmarking
6.20.4 Strategic Outlook
6.21 UPM Pharmaceuticals
6.21.1 Company Snapshot
6.21.2 Company Overview
6.21.3 Service Benchmarking
6.21.4 Strategic Outlook
6.22 Baxter Biopharma Solutions
6.22.1 Company Snapshot
6.22.2 Company Overview
6.22.3 Financial Analysis
6.22.3.1 Net Revenue, 2017-2021
6.22.3.2 Operating Income, 2017-2021
6.22.3.3 Net Income, 2017-2021
6.22.3.4 EBITDA, 2017-2021
6.22.3.5 Company Regional Revenue Market Share
6.22.3.6 Company Business Segments Analysis
6.22.4 Service Benchmarking
6.22.5 Strategic Outlook
6.23 Boston Scientific Corporation
6.23.1 Company Snapshot
6.23.2 Company Overview
6.23.3 Financial Analysis
6.23.3.1 Net Revenue, 2017-2021
6.23.3.2 Operating Income, 2017-2021
6.23.3.3 Net Income, 2017-2021
6.23.3.4 EBITDA, 2017-2021
6.23.3.5 Company Regional Revenue Market Share
6.23.3.6 Company Business Segments Analysis
6.23.4 Service Benchmarking
6.23.5 Strategic Outlook
6.24 Koninklijke DSM N.V. (Royal DSM)
6.24.1 Company Snapshot
6.24.2 Company Overview
6.24.3 Financial Analysis
6.24.3.1 Net Revenue, 2017-2021
6.24.3.2 Operating Income, 2017-2021
6.24.3.3 Net Income, 2017-2021
6.24.3.4 EBITDA, 2017-2021
6.24.4 Service Benchmarking
6.24.5 Strategic Outlook
6.25 CSL Limited
6.25.1 Company Snapshot
6.25.2 Company Overview
6.25.3 Financial Analysis
6.25.3.1 Net Revenue, 2017-2021
6.25.3.2 Operating Income, 2017-2021
6.25.3.3 Net Income, 2017-2021
6.25.3.4 EBITDA, 2017-2021
6.25.3.5 Company Regional Revenue Market Share
6.25.3.6 Company Business Segments Analysis
6.25.4 Service Benchmarking
6.25.5 Strategic Outlook
6.26 Lonza
6.26.1 Company Snapshot
6.26.2 Company Overview
6.26.3 Financial Analysis
6.26.3.1 Net Revenue, 2017-2021
6.26.3.2 Operating Income, 2017-2021
6.26.3.3 Net Income, 2017-2021
6.26.3.4 EBITDA, 2017-2021
6.26.3.5 Company Regional Revenue Market Share
6.26.3.6 Company Business Segments Analysis
6.26.4 Service Benchmarking
6.26.5 Strategic Outlook
6.27 McKesson Corporation
6.27.1 Company Snapshot
6.27.2 Company Overview
6.27.3 Financial Analysis
6.27.3.1 Net Revenue, 2017-2021
6.27.3.2 Operating Income, 2017-2021
6.27.3.3 Net Income, 2017-2021
6.27.3.4 EBITDA, 2017-2021
6.27.3.5 Company Regional Revenue Market Share
6.27.3.6 Company Business Segments Analysis
6.27.4 Product Benchmarking
6.27.5 Strategic Outlook
6.28 Edwards Lifesciences Corporation
6.28.1 Company Snapshot
6.28.2 Company Overview
6.28.3 Financial Analysis
6.28.3.1 Net Revenue, 2017-2021
6.28.3.2 Operating Income, 2017-2021
6.28.3.3 Net Income, 2017-2021
6.28.3.4 EBITDA, 2017-2021
6.28.3.5 Company Regional Revenue Market Share
6.28.3.6 Company Business Segments Analysis
6.28.4 Product Benchmarking
6.28.5 Strategic Outlook
6.29 Nipro Corporation
6.29.1 Company Snapshot
6.29.2 Company Overview
6.29.3 Service Benchmarking
6.29.4 Strategic Outlook
6.30 PPD Inc.
6.30.1 Company Snapshot
6.30.2 Company Overview
6.30.3 Service Benchmarking
6.30.4 Strategic Outlook
6.31 Grifols
6.31.1 Company Snapshot
6.31.2 Company Overview
6.31.3 Financial Analysis
6.31.3.1 Net Revenue, 2017-2021
6.31.3.2 Operating Income, 2017-2021
6.31.3.3 Net Income, 2017-2021
6.31.3.4 EBITDA, 2017-2021
6.31.4 Service Benchmarking
6.31.5 Strategic Outlook
6.32 bioMérieux
6.32.1 Company Snapshot
6.32.2 Company Overview
6.32.3 Financial Analysis
6.32.3.1 Net Revenue, 2017-2021
6.32.3.2 Operating Income, 2017-2021
6.32.3.3 Net Income, 2017-2021
6.32.3.4 EBITDA, 2017-2021
6.32.3.5 Company Regional Revenue Market Share
6.32.3.6 Company Business Segments Analysis
6.32.4 Product Benchmarking
6.32.5 Strategic Outlook
6.33 Aurobindo Pharma
6.33.1 Company Snapshot
6.33.2 Company Overview
6.33.3 Service Benchmarking
6.33.4 Strategic Outlook
6.34 Dr. Reddy's Laboratories Ltd.
6.34.1 Company Snapshot
6.34.2 Company Overview
6.34.3 Financial Analysis
6.34.3.1 Net Revenue, 2017-2021
6.34.3.2 Operating Income, 2017-2021
6.34.3.3 Net Income, 2017-2021
6.34.3.4 EBITDA, 2017-2021
6.34.3.5 Company Regional Revenue Market Share
6.34.3.6 Company Business Segments Analysis
6.34.4 Service Benchmarking
6.34.5 Strategic Outlook
6.35 WuXi AppTec
6.35.1 Company Snapshot
6.35.2 Company Overview
6.35.3 Service Benchmarking
6.35.4 Strategic Outlook
6.36 Huapont Life Sciences Co Ltd.
6.36.1 Company Snapshot
6.36.2 Company Overview
6.36.3 Service Benchmarking
6.37 ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.
6.37.1 Company Snapshot
6.37.2 Company Overview
6.37.3 Service Benchmarking
6.37.4 Strategic Outlook
6.38 Alkermes
6.38.1 Company Snapshot
6.38.2 Company Overview
6.38.3 Financial Analysis
6.38.3.1 Net Revenue, 2017-2021
6.38.3.2 Operating Income, 2017-2021
6.38.3.3 Net Income, 2017-2021
6.38.3.4 EBITDA, 2017-2021
6.38.4 Service Benchmarking
6.38.5 Strategic Outlook
6.39 Emergent BioSolutions
6.39.1 Company Snapshot
6.39.2 Company Overview
6.39.3 Financial Analysis
6.39.3.1 Net Revenue, 2017-2021
6.39.3.2 Operating Income, 2017-2021
6.39.3.3 Net Income, 2017-2021
6.39.3.4 EBITDA, 2017-2021
6.39.4 Service Benchmarking
6.39.5 Strategic Outlook
6.40 Divi's Laboratories Limited
6.40.1 Company Snapshot
6.40.2 Company Overview
6.40.3 Service Benchmarking
6.41 Bavarian Nordic
6.41.1 Company Snapshot
6.41.2 Company Overview
6.41.3 Financial Analysis
6.41.3.1 Net Revenue, 2017-2021
6.41.3.2 Operating Income, 2017-2021
6.41.3.3 Net Income, 2017-2021
6.41.3.4 EBITDA, 2017-2021
6.41.3.5 Company Regional Revenue Market Share
6.41.3.6 Company Business Segments Analysis
6.41.4 Service Benchmarking
6.41.5 Strategic Outlook
6.42 Strides Pharma Science Limited
6.42.1 Company Snapshot
6.42.2 Company Overview
6.42.3 Service Benchmarking
6.42.4 Strategic Outlook
6.43 Consort Medical plc
6.43.1 Company Snapshot
6.43.2 Company Overview
6.43.3 Service Benchmarking
6.43.4 Strategic Outlook
6.44 Catalent Inc.
6.44.1 Company Snapshot
6.44.2 Company Overview
6.44.3 Financial Analysis
6.44.3.1 Net Revenue, 2017-2021
6.44.3.2 Operating Income, 2017-2021
6.44.3.3 Net Income, 2017-2021
6.44.3.4 EBITDA, 2017-2021
6.44.3.5 Company Regional Revenue Market Share
6.44.3.6 Company Business Segments Analysis
6.44.4 Service Benchmarking
6.44.5 Strategic Outlook
6.45 Moderna Inc.
6.45.1 Company Snapshot
6.45.2 Company Overview
6.45.3 Financial Analysis
6.45.3.1 Net Revenue, 2017-2021
6.45.3.2 Operating Income, 2017-2021
6.45.3.3 Net Income, 2017-2021
6.45.3.4 EBITDA, 2017-2021
6.45.4 Service Benchmarking
6.45.5 Strategic Outlook
6.46 Avid Bioservices, Inc.
6.46.1 Company Snapshot
6.46.2 Company Overview
6.46.3 Financial Analysis
6.46.3.1 Net Revenue, 2017-2021
6.46.3.2 Operating Income, 2017-2021
6.46.3.3 Net Income, 2017-2021
6.46.3.4 EBITDA, 2017-2021
6.46.4 Service Benchmarking
6.46.5 Strategic Outlook
6.47 Novavax
6.47.1 Company Snapshot
6.47.2 Company Overview
6.47.3 Financial Analysis
6.47.3.1 Net Revenue, 2017-2021
6.47.3.2 Operating Income, 2017-2021
6.47.3.3 Net Income, 2017-2021
6.47.3.4 EBITDA, 2017-2021
6.47.4 Service Benchmarking
6.47.5 Strategic Outlook
6.48 INOVIO Pharmaceuticals
6.48.1 Company Snapshot
6.48.2 Company Overview
6.48.3 Financial Analysis
6.48.3.1 Net Revenue, 2017-2021
6.48.3.2 Operating Income, 2017-2021
6.48.3.3 Net Income, 2017-2021
6.48.3.4 EBITDA, 2017-2021
6.48.4 Service Benchmarking
6.48.5 Strategic Outlook
6.49 VBI Vaccines Inc.
6.49.1 Company Snapshot
6.49.2 Company Overview
6.49.3 Financial Analysis
6.49.3.1 Net Revenue, 2017-2021
6.49.3.2 Operating Income, 2017-2021
6.49.3.3 Net Income, 2017-2021
6.49.3.4 EBITDA, 2017-2021
6.49.4 Service Benchmarking
6.49.5 Strategic Outlook
6.50 Fresenius SE&Co. KGaA
6.50.1 Company Snapshot
6.50.2 Company Overview
6.50.3 Financial Analysis
6.50.3.1 Net Revenue, 2017-2021
6.50.3.2 Operating Income, 2017-2021
6.50.3.3 Net Income, 2017-2021
6.50.3.4 EBITDA, 2017-2021
6.50.3.5 Company Regional Revenue Market Share
6.50.3.6 Company Business Segments Analysis
6.50.4 Service Benchmarking
6.50.5 Strategic Outlook
7 Conclusion and Recommendations
7.1 Concluding Remarks from
7.2 Recommendations for Market Players
7.2.4 Biopharma Manufacturing Demand Will Drive Growth 2022-2032

$8,737
$4,977
$6,930
$5,670

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings